|
|
|
|
| LEADER |
04587nma a2201441 u 4500 |
| 001 |
EB002052600 |
| 003 |
EBX01000000000000001196266 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
220822 ||| eng |
| 020 |
|
|
|a 9783036547688
|
| 020 |
|
|
|a 9783036547671
|
| 020 |
|
|
|a books978-3-0365-4767-1
|
| 100 |
1 |
|
|a Kim, Jong Heon
|
| 245 |
0 |
0 |
|a Advances in Antifungal Development: Discovery of New Drugs and Drug Repurposing
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2022
|
| 300 |
|
|
|a 1 electronic resource (282 p.)
|
| 653 |
|
|
|a multidrug resistance
|
| 653 |
|
|
|a clotrimazole
|
| 653 |
|
|
|a yeasts
|
| 653 |
|
|
|a echinocandin resistance
|
| 653 |
|
|
|a Galleria mellonella model
|
| 653 |
|
|
|a yeast infection
|
| 653 |
|
|
|a isavuconazonium sulfate
|
| 653 |
|
|
|a drug targets
|
| 653 |
|
|
|a antifungal drugs
|
| 653 |
|
|
|a host-directed drug therapy
|
| 653 |
|
|
|a echinocandin drugs
|
| 653 |
|
|
|a mycology
|
| 653 |
|
|
|a Cryptococcus
|
| 653 |
|
|
|a membrane potential (ΔΨM)
|
| 653 |
|
|
|a azoles
|
| 653 |
|
|
|a synergy
|
| 653 |
|
|
|a Candida
|
| 653 |
|
|
|a microbiology
|
| 653 |
|
|
|a Acanthamoeba
|
| 653 |
|
|
|a therapeutic alternatives
|
| 653 |
|
|
|a emerging fungi
|
| 653 |
|
|
|a CAP64
|
| 653 |
|
|
|a drug
|
| 653 |
|
|
|a fission yeast
|
| 653 |
|
|
|a retinoids
|
| 653 |
|
|
|a Candida spp.
|
| 653 |
|
|
|a Research & information: general / bicssc
|
| 653 |
|
|
|a Biology, life sciences / bicssc
|
| 653 |
|
|
|a sporotrichosis
|
| 653 |
|
|
|a echinocandins
|
| 653 |
|
|
|a all-trans retinoic acid
|
| 653 |
|
|
|a cell integrity
|
| 653 |
|
|
|a nanoparticles
|
| 653 |
|
|
|a repositioning
|
| 653 |
|
|
|a 3-phenyl-1H-indazole
|
| 653 |
|
|
|a vaginitis
|
| 653 |
|
|
|a ultrastructure
|
| 653 |
|
|
|a drug design
|
| 653 |
|
|
|a indazole
|
| 653 |
|
|
|a viral infections
|
| 653 |
|
|
|a invasive aspergillosis treatment
|
| 653 |
|
|
|a beta-glucan
|
| 653 |
|
|
|a photodynamic treatment
|
| 653 |
|
|
|a Acanthamoeba keratitis
|
| 653 |
|
|
|a photosensitiser
|
| 653 |
|
|
|a drug delivery systems
|
| 653 |
|
|
|a resistance
|
| 653 |
|
|
|a drug repurposing
|
| 653 |
|
|
|a vulvovaginal
|
| 653 |
|
|
|a capsule
|
| 653 |
|
|
|a Fks resistance hot spots
|
| 653 |
|
|
|a mycosis
|
| 653 |
|
|
|a canesten
|
| 653 |
|
|
|a onychomycosis
|
| 653 |
|
|
|a β(1,3)-D-glucan synthase
|
| 653 |
|
|
|a polycations
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a polyenes
|
| 653 |
|
|
|a vaginal health
|
| 653 |
|
|
|a natural products
|
| 653 |
|
|
|a cell separation
|
| 653 |
|
|
|a pyrazole
|
| 653 |
|
|
|a septation
|
| 653 |
|
|
|a Candida auris
|
| 653 |
|
|
|a biological synthesis
|
| 653 |
|
|
|a cell lysis
|
| 653 |
|
|
|a new targets
|
| 653 |
|
|
|a Felis catus
|
| 653 |
|
|
|a acetylsalicylic acid (ASA, aspirin)
|
| 653 |
|
|
|a Malassezia spp.
|
| 653 |
|
|
|a cyst
|
| 653 |
|
|
|a marine
|
| 653 |
|
|
|a candida albicans
|
| 653 |
|
|
|a cytokinesis
|
| 653 |
|
|
|a candida
|
| 653 |
|
|
|a cell wall
|
| 653 |
|
|
|a hydrazones
|
| 653 |
|
|
|a candidosis
|
| 653 |
|
|
|a fungi
|
| 653 |
|
|
|a azole
|
| 653 |
|
|
|a drug discovery
|
| 653 |
|
|
|a zoonoses
|
| 653 |
|
|
|a antifungal
|
| 653 |
|
|
|a invasive fungal infections
|
| 653 |
|
|
|a quinones
|
| 653 |
|
|
|a anticandidal activity
|
| 653 |
|
|
|a antifungals
|
| 653 |
|
|
|a myconanotechnology
|
| 653 |
|
|
|a free-living ameba
|
| 653 |
|
|
|a dermatophytes
|
| 653 |
|
|
|a Aspergillus spp.
|
| 700 |
1 |
|
|a Cheng, Luisa W.
|
| 700 |
1 |
|
|a Land, Kirkwood
|
| 700 |
1 |
|
|a Kim, Jong Heon
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-0365-4767-1
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/5854
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/91208
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 000
|
| 082 |
0 |
|
|a 576
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 700
|
| 082 |
0 |
|
|a 600
|
| 520 |
|
|
|a This reprint describes recent advances made in the field of antifungal development, especially the discovery of new drugs and drug repurposing. The articles presented in this book provide useful information and insight for the development of new antifungal drugs or intervention strategies. The identification of new, safe molecules, and cellular targets, as well as the elucidation of their antifungal mechanisms of action, will further the effective control of fungal pathogens, especially those resistant to current therapeutic agents.
|